First Wave BioPharma Future Growth
Future criteria checks 0/6
First Wave BioPharma is forecast to grow earnings at 56.1% per annum. EPS is expected to grow by 119.1% per annum.
Key information
56.1%
Earnings growth rate
119.1%
EPS growth rate
Biotechs earnings growth | 30.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | N/A | -9 | N/A | N/A | 2 |
12/31/2022 | N/A | -14 | N/A | N/A | 2 |
9/30/2022 | N/A | -22 | -33 | -23 | N/A |
6/30/2022 | N/A | -57 | -44 | -34 | N/A |
3/31/2022 | N/A | -65 | -45 | -35 | N/A |
12/31/2021 | N/A | -85 | -43 | -32 | N/A |
9/30/2021 | N/A | -92 | -32 | -32 | N/A |
6/30/2021 | N/A | -74 | -19 | -19 | N/A |
3/31/2021 | N/A | -66 | -15 | -15 | N/A |
12/31/2020 | N/A | -42 | -11 | -11 | N/A |
9/30/2020 | N/A | -25 | -9 | -9 | N/A |
6/30/2020 | N/A | -15 | -10 | -10 | N/A |
3/31/2020 | N/A | -16 | -13 | -13 | N/A |
12/31/2019 | N/A | -15 | -14 | -14 | N/A |
9/30/2019 | N/A | -18 | -14 | -14 | N/A |
6/30/2019 | N/A | -16 | -13 | -13 | N/A |
3/31/2019 | N/A | -15 | -12 | -11 | N/A |
12/31/2018 | N/A | -14 | -11 | -11 | N/A |
9/30/2018 | N/A | -12 | -10 | -10 | N/A |
6/30/2018 | N/A | -13 | -9 | -9 | N/A |
3/31/2018 | N/A | -12 | -8 | -8 | N/A |
12/31/2017 | N/A | -11 | -7 | -7 | N/A |
9/30/2017 | N/A | -14 | -7 | -7 | N/A |
6/30/2017 | N/A | -14 | -7 | -7 | N/A |
3/31/2017 | N/A | -15 | -5 | -5 | N/A |
12/31/2016 | N/A | -15 | -5 | -5 | N/A |
9/30/2016 | N/A | -10 | -3 | -3 | N/A |
6/30/2016 | N/A | -8 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3660 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3660 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3660 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 3660's revenue is forecast to grow faster than the German market.
High Growth Revenue: 3660 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3660's Return on Equity is forecast to be high in 3 years time